New research builds on Nobel-winning immune checkpoint blockade work
Immunotherapy’s promise in the fight against cancer drew international attention after two scientists won a Nobel Prize this year for unleashing the ability of the immune system to eliminate tumor cells.
But their approach, which keeps cancer cells from shutting off the immune system’s powerful T-cells before they can fight tumors, is just one way to use the body’s natural defenses against deadly disease. A team of Vanderbilt University bioengineers today announced a major breakthrough in another: penetrating tumor-infiltrating immune cells and flipping on a switch that tells them to start fighting. The team designed a nanoscale particle to do that and found early success using it on human melanoma tissue.
“Tumors are pretty conniving and have evolved many ways to evade detection from our immune system,” said John T. Wilson, assistant professor of chemical and biomolecular engineering and biomedical engineering. “Our goal is to rearm the immune system with the tools it needs to destroy cancer cells.
“Checkpoint blockade has been a major breakthrough, but despite the huge impact it continues to have, we also know that there are a lot of patients who don’t respond to these therapies. We’ve developed a nanoparticle to find tumors and deliver a specific type of molecule that’s produced naturally by our bodies to fight off cancer.”
That molecule is called cGAMP, and it’s the primary way to switch on what’s known as the stimulator of interferon genes (STING) pathway: a natural mechanism the body uses to mount an immune response that can fight viruses or bacteria or clear out malignant cells. Wilson said his team’s nanoparticle delivers cGAMP in a way that jump-starts the immune response inside the tumor, resulting in the generation of T-cells that can destroy the tumor from the inside and also improve responses to checkpoint blockade.
While the Vanderbilt team’s research focused on melanoma, their work also indicates that this could impact treatment of many cancers, Wilson said, including breast, kidney, head and neck, neuroblastoma, colorectal and lung cancer.
His findings appear today in a paper titled “Endosomolytic Polymersomes Increase the Activity of Cyclic Dinucleotide STING Agonists to Enhance Cancer Immunotherapy” in the journal Nature Nanotechnology.
Daniel Shae, a Ph.D. student on Wilson’s team and first author of the manuscript, said the process began with developing the right nanoparticle, built using “smart” polymers that respond to changes in pH that he engineered to enhance the potency of cGAMP. After 20 or so iterations, the team found one that could deliver cGAMP and activate STING efficiently in mouse immune cells, then mouse tumors and eventually human tissue samples.
“That’s really exciting because it demonstrates that, one day, this technology may have success in patients,” Shae said.
The Latest on: Cancer Immunotherapy
via Google News
The Latest on: Cancer Immunotherapy
- Could T-Cell Therapy Be the Next Advancement in Lung Cancer Immunotherapy?on May 1, 2021 at 8:07 am
Over the past few years, lung cancer has changed significantly with improving outcomes, particularly attributable to immunotherapy, but how do we continue that trend?
- Engineering T cells to attack cancer broadlyon April 30, 2021 at 10:09 am
Through T cell engineering, researchers at Virginia Commonwealth University Massey Cancer Center show that it's possible to arrest tumor growth for a variety of cancers and squash the spread of cancer ...
- Two FDA Wins for Immunotherapy in Bladder Canceron April 29, 2021 at 11:31 am
In separate votes, an FDA advisory committee recommended that pembrolizumab (Keytruda) and atezolizumab (Tecentriq) hold on to accelerated approval as first-line therapy for advanced bladder cancer, ...
- Metabolic barriers to cancer immunotherapyon April 29, 2021 at 10:26 am
Immunotherapeutic approaches to cancer can be affected by metabolic restrictions that limit the potency of anticancer T cell responses. In this Review, DePeaux and Delgoffe discuss the metabolic ...
- Cancer Immunotherapy Market Development And Future Trendson April 29, 2021 at 9:33 am
Market growth influenced due to following factors- Increasing adoption of target therapy over traditional therapy. Emergence of biosimilars. Increasing demand for mAbs and high prevalence of cancer.
- Lung Cancer Survival Continues to Rise With Immunotherapyon April 29, 2021 at 9:06 am
Twice as many patients with advanced lung cancer carrying high PD-L1 expression lived 5 years or longer if they started treatment with pembrolizumab (Keytruda) instead of chemotherapy, long-term ...
- Cancer Immunotherapy Market Size, Share | Global Industry Report, 2025on April 27, 2021 at 10:38 pm
Cancer Immunotherapy Market Opportunities, Size, Share, Emerging Trends, Technological Innovation, Forecasts & Regional Analysis (Latin America, North America, Asia Pacific, Europe, Middle East) "The ...
- Genetic changes in head and neck cancer, immunotherapy resistance identifiedon April 26, 2021 at 1:17 pm
A multi-institutional team of researchers has identified both the genetic abnormalities that drive pre-cancer cells into becoming an invasive type of head and neck cancer and patients who are least ...
- Cancer Immunotherapy Market: Current Analysis and Forecast 2021-2027on April 26, 2021 at 8:00 am
A comprehensive overview of the Cancer Immunotherapy market is recently added by UnivDatos Market Insights to its humongous database. The Cancer Immunotherapy Market ...
- FDA Approves New Immunotherapy for Endometrial Canceron April 22, 2021 at 3:19 pm
The accelerated approval for dostarlimab is for use in patients with recurrent or advanced endometrial cancers with deficient mismatch repair (dMMR).
via Bing News